About Napp

We’re in the business of bringing medicines to the NHS. It is work that deeply affects the lives of health providers and patients – and here at Napp we pride ourselves on doing it the right way.

The UK is not just our market, it’s our home. We’re a privately owned UK company with a strong track record in bringing high quality, innovative medicines to UK healthcare professionals and their patients.

Please visit us regularly to find the latest information.

Person

Therapy Areas

  • Biosimilars
  • Cardiovascular
  • Diabetes
  • Oncology
  • Pain Management & Supportive Care
  • Respiratory

Important Safety Information

Therapy Areas

Important Safety Information

Events & Resources

  • Upcoming Events
  • On Demand
  • Articles
  • Other Resources

Upcoming Events

Mental health 14 oct

Therapy Areas: Diabetes

A series of bitesize meetings for HCP’s Managing T2DM: Prioritising Type 2 Diabetes Mellitus

Mental health 7 oct

Therapy Areas: Diabetes

A series of bitesize meetings for HCP’s Managing T2DM: Diabetic Kidney Disease in T2DM; the Importance of Identification and Treatment

Mental health 7 oct

Therapy Areas: Diabetes

A series of bitesize meetings for HCP’s Managing T2DM: Achieving a Legacy Effect in Type 2 Diabetes Mellitus, Audit and QOF

On Demand

Sarah

SGLT2is: The New Standard of Care for Diabetic Kidney Disease

T2DM Expert Talks is a series of interviews with national and international experts sharing their best practices and views on diabetes treatment, guidelines and patient care.

In this interview, Dr. Davies will talk about how to identify patients with diabetic kidney disease. She will further expand on the new standard of care, now available, as recommended by international guidelines.

Dr. Sarah Davies

MBBCh (hons), FRCP, MRCGP, PGDip

Clinical Director for Diabetes in Primary Care

for Cardiff and Vale University Health Board

  • English
  • 00:08:51
  • Diabetes
  • webinar
  • T2DM Expert Talks, Promotional Content
An image explaining KDIGO guidelines

How to use KDIGO Guidelines for Managing CKD in Type 2 Diabetes

T2DM Expert Talks is a series of interviews with national and international experts sharing their best practices and views on diabetes treatment, guidelines and patient care.

The interview focuses on the key KDIGO recommendations pertinent to the following issues in patients
with T2DM and CKD: glycaemic monitoring and targets, current management and recommendations,
treatment algorithm and approach, evidence on oral SGLT2i based on current UK licence indications.

Dr. David Wheeler

Dr. David Wheeler, MBChB, MRCP, MD, FRCGP

Professor of Kidney Medicine at University College London and Honorary

Consultant Nephrologist at the Royal Free London NHS Foundation Trust, UK

  • English
  • 00:06:50
  • Diabetes
  • webinar
  • T2DM Expert Talks, Promotional Content
Credence Trial webinar thumbnail image

Update on the latest evidence of SGLT2i: A practical guide to their use

The session will provide a clear understanding of the latest evidence for the SGLT2i class, consider the practicalities of their use and their position in the treatment guidelines, as well as exploring and understanding the concept of therapeutic inertia assisting you in improving your type 2 diabetes mellitus patient outcomes.

Professor Melanie Davies

Professor Melanie Davies,

Professor of Diabetes Medicine,

Leicester Diabetes Centre

  • English
  • 00:50:30
  • Diabetes
  • webinar
  • Promotional Content

SURPASS-1: tirzepatide vs. placebo

Novel dual GIP and GLP-1 receptor agonist tirzepatide as monotherapy in T2DM demonstrated clinically significant reductions in HbA1c and bodyweight without increased risk of clinically significant or severe hypoglycaemia vs placebo in the SURPASS-1 trial.

Read More

SURPASS-2: tirzepatide vs. semaglutide

Results from the open-label, randomised SURPASS-2 trial, assessing the novel dual GIP (glucose-dependent insulinotropic polypeptide)/GLP-1 (glucagon-like peptide 1) receptor agonist tirzepatide vs. human GLP-1 receptor agonist semaglutide in 1,878 type 2 diabetes patients inadequately controlled with metformin, conferred statistically significant HbA1c and body weight reductions from baseline compared to semaglutide in all three treatment arms (tirzepatide 5 mg, 10 mg, and 15 mg).

Read More

AMPLITUDE-O: efpeglenatide becomes the first long-acting exendin-based GLP-1 receptor agonist to show CV and renal benefits in type 2 diabetes

This cardiovascular outcomes trial evaluated efpeglenatide in 4076 participants with type 2 diabetes and either a history of cardiovascular (CV) disease or current kidney disease plus at least one other cardiovascular risk factor. Participants were randomly assigned 1:1:1 to receive weekly subcutaneous injections of efpeglenatide at a dose of 4 or 6 mg or placebo.

Read More
Triple protection Info

Infographics

Triple Protection Infographics

credence

Infographics

CREDENCE study